Blog

Posts Tagged ‘drug stocks’

Adding Nektar call options to my Volatility Portfolio–again

Again. I'm adding the January 17, 2020 Call Options with a strike at $35 on Nektar Theraeutics (NKTR) to my Volatility Portfolio on JubakAM.com and JugglingWithKnives.com. (Ticker on these options is NKTR200117C00035000.) The underlying shares closed at $33.70, up 0.90% on June 14. I've traded these options before with a spectacular realized gain of better than […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Incyte adds to Jakafi label with new FDA approval

Jubak Picks and Volatility Portfolio member Incyte (INCY) closed up 1.55% today to $81.75 on news that the U.S. Food and Drug Administration had approved the company's Jakafi for treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant. The drug can now be prescribed to […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

JNJ earnings a tale of two companies

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Dividend Portfolio member Merck continues Keytruda momentum

Merck's cancer drug Keytruda continues to build global momentum. Today Merck (MRK) announced that China has approved Keytruda for first-line treatment of metastatic nonsquamous non-small cell lung cancer in combination with chemotherapy. The stock, which is a member of my Dividend Portfolio, is up 015% today as of 2:20 p.m. New York time. The shares […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Government action on drug prices seems far, far away

The format was familiar: Seven CEOs sit in front of a Senate Committee probing their industry's business practices. But whereas a Congressional hearing a decade ago marked a key moment in what was a costly public reckoning for the tobacco industry, today's hearing produced little more than a consensus among Senators that drug pricing is […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Adding Ionis Pharmacueticals to my Special Report: 10 Best Buy Stocks for After the Bear–and to my Volatility Portfolio

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Syneos, another small cap stock to watch (or to buy if you think the bear is over)

Back on November 27, I launched a "Special Report: My 10 small company stock picks for the January Effect." What with tremendous volatility in the market, the beginning of a bear market for some sectors, and the failure of the January Effect to arrive on schedule in December, I never finished the list. I fact […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Buying Pfizer for my Dividend Portfolio

I'm going to take advantage of the selling in the market in general and in the drug sector in particular--on news of the asbestos liability at Johnson & Johnson and fears of the death of Obamacare (AKA the Affordable Care Act)--to buy Pfizer (PFE) in my Dividend Portfolio. The stock is down 1.58% again today, […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Sangamo makes regulatory progress; adding it to Special Report “Picks for a January Effect Rally”

As an investor in Sangamo (SGMO) the very slow and cautious pace of regulatory action at the U.S. Food & Drug Administration is frustrating. The FDA has only slowly allowed the company to expand the number of patients enrolled in the the safety trials for its new in vivo gene editing technology. As a human […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Incyte knocking on the door of a new upward trend after today’s 6% pop

Reports of results from the December 1-4 meeting of the American Society of Hematology continue to move biotech stocks. Today it was Incyte's (INCY) turn. The company announced positive results for a Phase 2 trial evaluating Incyte's Jakafi in combination with corticosteroids in patients with acute graft-versus-host disease who failed to respond adequately to corticosteroids […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.